Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc (NQ: BEAM )

32.64 -0.58 (-1.75%)
Streaming Delayed Price Updated: 11:14 AM EDT, Mar 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 230,645
Open 33.00
Bid (Size) 32.60 (3)
Ask (Size) 32.74 (4)
Prev. Close 33.22
Today's Range 32.01 - 33.19
52wk Range 27.77 - 73.27
Shares Outstanding 72,397,631
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Beam Therapeutics to Participate in the Barclays 2023 Global Healthcare Conference
From Beam Therapeutics
Via Globe NewsWire
3 CRISPR Gene Editing Stocks to Consider for Ground-Floor Investing
CRISPR Therapeutics, Beam Therapeutics and Vertex Pharmaceuticals are three CRISPR gene editing stocks you won't want to miss out on. 
Via InvestorPlace

Performance

YTD
-12.54%
-12.54%
1 Month
-24.39%
-24.39%
3 Month
-18.60%
-18.60%
6 Month
-39.32%
-39.32%
1 Year
-44.80%
-44.80%

More News

Read More
3 Game-Changing Stocks to Buy in March
Via The Motley Fool
The Top 7 Growth Stocks in Biotech
Via InvestorPlace
Where Beam Therapeutics Stands With Analysts
Via Benzinga
Analyst Ratings for Beam Therapeutics
Via Benzinga
4 Analysts Have This to Say About Beam Therapeutics
Via Benzinga
BMO Capital Upgrades Beam Therapeutics: Here's What You Need To Know
Via Benzinga
Beam Therapeutics to Participate in the 43rd Annual Cowen Healthcare Conference
From Beam Therapeutics
Via Globe NewsWire
Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
From Beam Therapeutics
Via Globe NewsWire
Better Buy: Beam Therapeutics or Intellia Therapeutics?
Via The Motley Fool
Beam Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
From Beam Therapeutics
Via Globe NewsWire
3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129%
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023
Via Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
Via InvestorPlace
5 Top Stocks for February
Via The Motley Fool
3 Great Growth Stocks Down 20% or More to Buy Now
Via The Motley Fool
A New Bull Market Is Coming: 3 Stocks That Could Skyrocket
Via The Motley Fool
3 Stocks That Could Create Lasting Generational Wealth
Via The Motley Fool
Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones
From Beam Therapeutics
Via Globe NewsWire
Cathie Wood Gets Elon Musk's Attention Over Gene-Editing Therapy Potential: 'Investors Chased The Dream Then. Now, They're Running Away'
Via Benzinga
Beam Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Beam Therapeutics
Via Globe NewsWire
3 Under-the-Radar Biotech Stocks to Buy in 2022
Via The Motley Fool
Analyst Beefs Up Beam Therapeutics Price Target, Says 'Reward Is Now Skewed To Upside'
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.